Results of a non-randomized, open-label phase I study evaluating the novel Immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa
BackgroundDespite the high morbidity and severe consequences of epidermolysis bullosa (EB), current treatments remain inadequate, lacking efficacy and the ability to target the microbial and inflammatory components of EB wounds. In this first-in-human open-label, single-arm study—part 3 of a 3-part Phase 1 clinical trial—we examined the safety, tolerability, and systemic exposure of topically appl
